July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion
Author Affiliations & Notes
  • Vaidehi Dedania
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Cem Ozgonul
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Cagri G Besirli
    Ophthalmology and Visual Sciences, Kellogg Eye Center/University of Michigan, New York, New York, United States
  • Footnotes
    Commercial Relationships   Vaidehi Dedania, None; Cem Ozgonul, None; Cagri Besirli, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4287. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vaidehi Dedania, Cem Ozgonul, Cagri G Besirli; Aflibercept versus bevacizumab and/or ranibizumab for recurrent macular edema secondary to central retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4287.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare functional and anatomic outcomes of treatment with intravitreal aflibercept versus bevacizumab and/or ranibizumab in patients with recurrent macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Methods : Retrospective, comparative case series of patients with recurrent ME in the setting of CRVO. Patients with recurrent ME received treatment with aflibercept (Group 1, G1) or bevacizumab and/or ranibizumab (Group 2, G2). Primary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT).

Results : Of the 20 eyes (20 patients) with recurrent ME included in the study, 9 received aflibercept (G1) and 11 received bevacizumab and/or ranibizumab (G2). Median BCVA at recurrence of ME and at most recent follow-up was 20/60 (G1) and 20/80 (G2) and 20/40 (G1) and 20/50 (G2, p> 0.05 for all comparisons), respectively. Median CFT at recurrence of ME and at most recent follow-up was 492 μm (G1) and 448 μm (G2) and 291 μm (G1) and 295 μm (G2, p> 0.05 for all comparisons), respectively. Complete resolution of ME for at least 4 months was found in 78% (G1) and 55% (G2) of patients with a median injection free interval of 11 (G1) and 13 (G2) months (p> 0.05).

Conclusions : In patients with recurrent ME secondary to CRVO, there was improvement in BCVA and CFT in all groups, although patients treated with aflibercept showed a trend toward better anatomical outcomes decreased need for recurrent injections.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).

Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) in Groups 1 and 2.* (A) There was a decline in BCVA in both groups at the time of recurrence, but improvement after treatment with aflibercept (Group 1) or bevacizumab and/or ranibizumab (Group 2). (B) CFT increased at the time of recurrence of macular edema and decreased after treatment with aflibercept (Group 1) and bevacizumab and/or ranibizumab (Group 2).

 

Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).

Figure 2. Spectral-domain optical coherence tomography of a patient in Group 1. A 72-year-old man with (A) complete resolution of macular edema (ME) after 3 injections of bevacizumab (BCVA 20/30, CFT = 297 μm), (B) recurrence of ME after 6 months (BCVA 20/50, CFT = 551 μm) and (C) complete resolution of ME after 4 monthly injections of aflibercept without recurrence 21 months after the last aflibercept injection (BCVA 20/25, CFT = 289 μm).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×